James D Rizzo, MD | Medical College of Wisconsin

James D. Rizzo, MD

Professor

view physician profile

Locations

Froedtert Hospital
Cancer Center - Froedtert Hospital

Specialties

Hematology
Medical Oncology

Languages

English

Education

MD - Doctor of Medicine

Biography

Dr. Rizzo is an attending physician in the MCW adult HCT unit, with clinical interests in hematologic malignancies and late effects of HCT. He completed a fellowship in hematology/oncology and a Robert Wood Johnson fellowship in epidemiology and cost-effectiveness research at Johns Hopkins University and holds an MS degree in epidemiology from MCW. He has taken a leadership role in several American Society of Hematology initiatives and participated in several committees. He is also an active member of the American Society for Blood and Marrow Transplant Quality Outcomes, Standardization of Outcomes, and Evidence Based Review Steering Committees.

Research Interests

Dr. J. Douglas Rizzo has ten years of experience with the Center for International Blood and Marrow Transplant Research (CIBMTR) at the Medical College of Wisconsin, an internationally recognized research organization. In his role as CIBMTR Senior Scientific Director and CIBMTR program leader for observational research, he has had primary responsibility for data operations and management staff oversight. He is responsible for implementation of the Stem Cell Therapeutics Outcomes Database at the CIBMTR, part of the national C.W. Bill Young Cell Transplantation Program. His research interests include late effects and quality of life after Hematopoietic Cell Transplantation (HCT), access to HCT across gender and ethnic/racial groups and other health policy issues.

Adding Centralized Electronic Patient-Reported Outcome Data Collection to an Established International Clinical Outcomes Registry.

(Cusatis R, Flynn KE, Vasu S, Pidala J, Muffly L, Uberti J, Tamari R, Mattila D, Mussetter A, Bruzauskas R, Chen M, Leckrone E, Myers J, Mau LW, Rizzo JD, Saber W, Horowitz M, Lee SJ, Burns LJ, Shaw B.) Transplant Cell Ther. 2022 02;28(2):112.e1-112.e9 PMID: 34757219 PMCID: PMC8915447 SCOPUS ID: 2-s2.0-85121127060 11/11/2021
COVID-19 and Hematopoietic Cell Transplantation Center-Specific Survival Analysis: Can We Adjust for the Impact of the Pandemic? Recommendations of the COVID-19 Task Force of the 2020 Center for International Blood and Marrow Transplantation Research Center Outcomes Forum.

(Wingard JR, Ahn KW, Dandoy C, Perales MA, Wood WA, Logan B, Riches M, Rizzo JD.) Transplant Cell Ther. 2021 07;27(7):533-539 PMID: 33895401 PMCID: PMC8061634 SCOPUS ID: 2-s2.0-85107113196 04/26/2021
Community health status and outcomes after allogeneic hematopoietic cell transplantation in the United States.

(Hong S, Brazauskas R, Hebert KM, Ganguly S, Abdel-Azim H, Diaz MA, Beattie S, Ciurea SO, Szwajcer D, Badawy SM, Gratwohl AA, LeMaistre C, Aljurf MDSM, Olsson RF, Bhatt NS, Farhadfar N, Yared JA, Yoshimi A, Seo S, Gergis U, Beitinjaneh AM, Sharma A, Lazarus H, Law J, Ulrickson M, Hashem H, Schoemans H, Cerny J, Rizzieri D, Savani BN, Kamble RT, Shaw BE, Khera N, Wood WA, Hashmi S, Hahn T, Lee SJ, Rizzo JD, Majhail NS, Saber W.) Cancer. 2021 02 15;127(4):609-618 PMID: 33085090 PMCID: PMC7855526 SCOPUS ID: 2-s2.0-85092920705 10/22/2020
The IL-6 antagonist tocilizumab is associated with worse depression and related symptoms in the medically ill.

(Knight JM, Costanzo ES, Singh S, Yin Z, Szabo A, Pawar DS, Hillard CJ, Rizzo JD, D'Souza A, Pasquini M, Coe CL, Irwin MR, Raison CL, Drobyski WR.) Transl Psychiatry. 2021 01 18;11(1):58 PMID: 33462203 PMCID: PMC7812704 SCOPUS ID: 2-s2.0-85100097244 01/20/2021
Corrigendum to ‘Ixazomib for chronic Graft-Versus-Host Disease prophylaxis following allogeneic hematopoietic cell transplantation’ [Biology of Blood and Marrow Transplantation 26/10 (2020) 1876-1885] (Biology of Blood and Marrow Transplantation (2020) 26/10(1876-1885) (S1083879120304146), (10.1016/j.bbmt.2020.07.005))

(Chhabra S, Visotcky A, Pasquini MC, Zhu F, Tang X, Zhang MJ, Thompson R, Abedin S, D'Souza A, Dhakal B, Drobyski WR, Fenske TS, Jerkins JH, Rizzo JD, Runaas L, Saber W, Shah NN, Shaw BE, Horowitz MM, Hari PN, Hamadani M.) Transplantation and Cellular Therapy. 2021 SCOPUS ID: 2-s2.0-85101258094 01/01/2021
Corrigendum to ‘Current Use and Trends in Hematopoietic Cell Transplantation in the United States’ [Transplantation and Cellular Therapy 26/8 (2020) e177-e182] (Transplantation and Cellular Therapy (2020) 26/8(e177-e182) (S1083879120302251), (10.1016/j.bbmt.2020.04.013))

(D'Souza A, Fretham C, Lee SJ, Arora M, Brunner J, Chhabra S, Devine S, Eapen M, Hamadani M, Hari P, Pasquini MC, Perez W, Phelan RA, Riches ML, Rizzo JD, Saber W, Shaw BE, Spellman SR, Steinert P, Weisdorf DJ, Horowitz MM.) Transplantation and Cellular Therapy. 2021 SCOPUS ID: 2-s2.0-85108559179 01/01/2021
Ixazomib for Chronic Graft-versus-Host Disease Prophylaxis following Allogeneic Hematopoietic Cell Transplantation.

(Chhabra S, Visotcky A, Pasquini MC, Zhu F, Tang X, Zhang MJ, Thompson R, Abedin S, D'Souza A, Dhakal B, Drobyski WR, Fenske TS, Jerkins JH, Douglas Rizzo J, Runaas L, Saber W, Shah NN, Shaw BE, Horowitz MM, Hari PN, Hamadani M.) Biol Blood Marrow Transplant. 2020 10;26(10):1876-1885 PMID: 32653622 PMCID: PMC7571859 SCOPUS ID: 2-s2.0-85089134303 07/13/2020
Current Use of and Trends in Hematopoietic Cell Transplantation in the United States.

(D'Souza A, Fretham C, Lee SJ, Arora M, Brunner J, Chhabra S, Devine S, Eapen M, Hamadani M, Hari P, Pasquini MC, Perez W, Phelan RA, Riches ML, Rizzo JD, Saber W, Shaw BE, Spellman SR, Steinert P, Weisdorf DJ, Horowitz MM.) Biol Blood Marrow Transplant. 2020 08;26(8):e177-e182 PMID: 32438042 PMCID: PMC7404814 SCOPUS ID: 2-s2.0-85085969206 05/22/2020
Hematopoietic Cell Transplantation with Cryopreserved Grafts for Severe Aplastic Anemia.

(Eapen M, Zhang MJ, Tang XY, Lee SJ, Fei MW, Wang HL, Hebert KM, Arora M, Chhabra S, Devine SM, Hamadani M, D'Souza A, Pasquini MC, Phelan R, Rizzo JD, Saber W, Shaw BE, Weisdorf DJ, Horowitz MM.) Biol Blood Marrow Transplant. 2020 07;26(7):e161-e166 PMID: 32389803 PMCID: PMC7206419 SCOPUS ID: 2-s2.0-85084668943 05/12/2020
Comparison of Patient Age Groups in Transplantation for Myelodysplastic Syndrome: The Medicare Coverage With Evidence Development Study.

(Atallah E, Logan B, Chen M, Cutler C, Deeg J, Jacoby M, Champlin R, Nishihori T, Confer D, Gajewski J, Farnia S, Greenberg P, Warlick E, Weisdorf D, Saber W, Horowitz MM, Rizzo JD.) JAMA Oncol. 2020 04 01;6(4):486-493 PMID: 31830234 PMCID: PMC6990739 SCOPUS ID: 2-s2.0-85076620276 12/13/2019
Propranolol inhibits molecular risk markers in HCT recipients: a phase 2 randomized controlled biomarker trial.

(Knight JM, Rizzo JD, Hari P, Pasquini MC, Giles KE, D'Souza A, Logan BR, Hamadani M, Chhabra S, Dhakal B, Shah N, Sriram D, Horowitz MM, Cole SW.) Blood Adv. 2020 02 11;4(3):467-476 PMID: 32027744 PMCID: PMC7013267 SCOPUS ID: 2-s2.0-85082178004 02/07/2020
Molecular Correlates of Socioeconomic Status and Clinical Outcomes Following Hematopoietic Cell Transplantation for Leukemia.

(Knight JM, Rizzo JD, Wang T, He N, Logan BR, Spellman SR, Lee SJ, Verneris MR, Arevalo JMG, Cole SW.) JNCI Cancer Spectr. 2019 Dec;3(4):pkz073 PMID: 31763620 PMCID: PMC6859844 SCOPUS ID: 2-s2.0-85085522039 11/26/2019